Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
J. Clin. Invest. I.R. Garrett, et al. 111:1771 doi:10.1172/JCI16198 [
Go to this article.]
Figure 1Proteasome inhibitors stimulate bone formation in vitro and in vivo. (
a–
e) Histologic sections of cultured murine neonatal calvarial bones treated with either (
a) media alone, (
b) lactacystin (2.5 μM), (
c) PS1 (0.1 μM), (
d) epoxomicin (0.01 μM), or (
e) eponemycin (0.5 μM). (
f–
i) Histologic sections, BFR, and MAR of murine proximal tibia from mice treated daily for 5 days and sacrificed 16 days later. (
f) Vehicle, (
g) PTH (0.08 mg/kg/day subcutaneously), (
h) PS1 (2 mg/kg/day subcutaneously), (
i) epoxomicin (0.1 mg/kg/day intraperitoneally). Values in parentheses are percentage of change from vehicle-treated controls. BV/TV bone volume/tissue volume. *
P < 0.05.
